SkinBioTherapeutics PLC Update on human study and IP portfolio extension (6644O)
January 31 2019 - 3:35AM
UK Regulatory
TIDMSBTX
RNS Number : 6644O
SkinBioTherapeutics PLC
31 January 2019
SkinBioTherapeutics plc
Interim update on human studies and extension of IP
portfolio
Manchester, UK - 31 January 2019 - SkinBioTherapeutics plc (AIM:
SBTX - "SkinBioTherapeutics" or the "Company"), a life science
company focused on skin health, provides interim data on the third
and final phase of its human studies and an update on one of its
patents.
SkinBioTherapeutics has completed testing on 60 of the total 120
volunteers for its human study, with no compliance or safety
concerns. The final 60 volunteers are now being treated and the
Company remains on track to complete the study during Q1 2019 as
expected.
The study is double-blinded, meaning neither the volunteers nor
the experimenters know who is receiving a particular treatment, to
prevent any bias. For this reason, SkinBioTherapeutics will need
the full dataset before it can be 'unblinded' for statistical
analysis. The data will then be assessed to determine effectiveness
- whether the SkinBiotix(R) technology retains the same beneficial
property of improving skin health when in a cream formulation.
The resulting safety, irritancy and effectiveness data will be
shared with potential global partners interested in commercialising
the SkinBiotix(R) technology. A number of these companies have
provided input into the study testing and analysis protocols.
In addition to the interim human study data, the Company has
expanded its patent portfolio, with a patent proceeding to grant in
Mexico. Adding protection around the SkinBiotix(R) technology is a
key part of the Company's strategy. This patent will add to those
already granted in Australia, New Zealand and Russia and a number
of other patent applications are in process.
Dr Cath O'Neill, CEO of SkinBioTherapeutics, commented:
"We have now recruited all 120 volunteers and, at this mid-way
point, there are no safety concerns. We remain on schedule to
complete the human study during the first quarter of 2019.
"Being able to determine the potential for our SkinBiotix(R)
technology as a clinically effective solution to improve skin
health allows us to actively progress discussions with partners
interested in commercialising the technology as a cosmetic.
"We are also determined to protect our intellectual property,
hence the expansion of our patent portfolio."
The information communicated within this announcement is deemed
to constitute inside information as stipulated under the Market
Abuse Regulations (EU) No. 596/2014 and has been arranged for
release by Doug Quinn, CFO of the Company. Upon the publication of
this announcement, this inside information is now considered to be
in the public domain.
-ENDS-
For more information, please contact:
SkinBioTherapeutics plc Tel: +44 (0) 161 468
Dr. Cath O'Neill, CEO 2760
Doug Quinn, CFO
Cairn Financial Advisers LLP (Nominated Tel: +44 (0) 20 7213
Adviser) 0880
Tony Rawlinson / Sandy Jamieson / Richard
Nash
Turner Pope Investments (Joint Broker) Tel: +44 (0) 20 3621
Ben Turner / James Pope 4120
Northland Capital Partners (Joint Broker)
Dugald Carlean Tel: +44 (0) 20 3861
6625
Instinctif Partners (Media Relations) Tel: +44 (0) 20 7457
Melanie Toyne-Sewell / Deborah Bell 2020
SkinBio@instinctif.com
About SkinBioTherapeutics plc
SkinBioTherapeutics is a life science company focused on skin
health. The Company's proprietary platform technology,
SkinBiotix(R), is based upon discoveries made by CEO Dr. Catherine
O'Neill and Professor Andrew McBain.
SkinBioTherapeutics' platform applies research discoveries made
on the activities of lysates derived from probiotic bacteria when
applied to the skin. The Company has shown that the SkinBiotix(R)
platform can improve the barrier effect of skin models, protect
skin models from infection and repair skin models. Proof of
principle studies have shown that the SkinBiotix(R) platform has
beneficial attributes applicable to each of these areas.
SkinBioTherapeutics received seed funding from the Tech Transfer
office of the University of Manchester for the discovery of
SkinBiotix(R). The platform was subsequently spun out of the
University of Manchester in March 2016 and was funded by OptiBiotix
(AIM: OPTI).
The Company joined AIM in April 2017, concurrent with raising
GBP4.5 million from a placing of new ordinary shares.
The Company is based in Manchester, UK. For more information,
visit www.skinbiotherapeutics.com.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCFMGFMRMZGLZG
(END) Dow Jones Newswires
January 31, 2019 03:35 ET (08:35 GMT)
Skinbiotherapeutics (LSE:SBTX)
Historical Stock Chart
From Apr 2024 to May 2024
Skinbiotherapeutics (LSE:SBTX)
Historical Stock Chart
From May 2023 to May 2024